Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: A study from the Acute Leukemia French Association (ALFA)

Blood

Volumn 100, Issue 8, 2002, Pages 2717-2723

  Preudhomme, Claude ^a,b,c   Sagot, Christophe ^a,b,c   Boissel, Nicolas ^a,b,c   Cayuela, Jean Michel ^a,b,c   Tigaud, Isabelle ^a,b,c   De Botton, Stéphane ^a,b,c   Thomas, Xavier ^a,b,c   Raffoux, Emmanuel ^a,b,c   Lamandin, Charlotte ^a,b,c   Castaigne, Sylvie ^a,b,c   Fenaux, Pierre ^a,b,c   Dombret, Hervé ^a,b,c  

^a INSERM   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; CCAAT ENHANCER BINDING PROTEIN ALPHA; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; FLT3 LIGAND; METHOTREXATE; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; FRANCE; GENE EXPRESSION; GENE LOCATION; GENE MUTATION; GENE SEQUENCE; GENETIC RISK; HIGH RISK POPULATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

EID: 0037108111     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-03-0990     Document Type: Article

References (20)

1. McKnight SL. McBindall-a better name for CCAAT/enhancer binding proteins? Cell. 2001; 107:259-261.
2. Lekstrom-Himes J, Xanthopoulos KG. Biological role of the CCAAT/enhancer-binding protein family of transcription factors. J Biol Chem. 1998;273: 28545-28548.
3. Tenen DG, Hromas R, Licht JD, Zhang DE. Transcription factors, normal myeloid development, and leukemia. Blood. 1997;90:489-519.
4. Johansen LM, Iwama A, Lodie TA, et al. c-Myc is a critical target for C/EBPα in granulopoiesis. Mol Cell Biol. 2001;21:3789-3806.
5. Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein α-deficient mice. Proc Natl Acad Sci U S A. 1997;94:569-574.
6. Tenen DG. Abnormalities of the CEBP α transcription factor: a major target in acute myeloid leukemia. Leukemia. 2001;15:688-689.
7. Pabst T, Mueller BU, Zhang P, et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia. Nat Genet. 2001;27:263-270.
8. Gombart AF, Hofmann WK, Kawano S, et al. Mutations in the gene coding for the transcription factor CCAAT/enhancer binding protein α in myelodysplastic syndromes and acute myeloid leukemias. Blood. 2002;99:1332-1340.
9. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322-2333.
10. Boissel N, Cayuela JM, Preudhomme C, et al. Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia. In press.
11. Castaigne S, Archimbaud E, Bordessoule D, et al. Sequential induction or double induction chemotherapy increase disease-free survival compared to "3+7" chemotherapy in less than 50 years adults with acute myeloid leukemia [abstract]. Blood. 1996;88(suppl 1):291a.
12. Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990;8: 813-819.
13. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
14. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc. 1972;135: 185-206.
15. Cox D. Regression models and life-tables. J R Stat Soc. 1972;34:187-220.
16. Williamson EA, Xu HN, Gombart AF, et al. Identification of transcriptional activation and repression domains in human CCAAT/enhancer-binding protein epsilon. J Biol Chem. 1998;273:14796-14804.
17. Williams SC,Angerer ND, Johnson PF. C/EBP proteins contain nuclear localization signals imbedded in their basic regions. Gene Expr. 1997;6: 371-385.
18. Fröhling S, Breitruck J, Schlenk R, et al. FLT3 internal tandem duplications and survival in adult acute myeloid leukemia: analysis of 188 intensively treated patients [abstract]. Blood. 2001;98: 717a.
19. Pabst T, Mueller BU, Harakawa N, et al. AML1-ETO downregulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemia. Nat Med. 2001;7:444-451.
20. Lodie TA, Radomska HS, Donato JD, et al. PML/RARa induces ATRA-sensitive delocalization of the critical granulocytic differentiation factor C/EBPα to a microspeckled nuclear pattern in t(15;17) APL [abstract]. Blood. 1999;94:692a.